Platelet-Rich Plasma: Where Are We Now and Where Are We Going?

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?

Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?

Soft tissue injury is a major source of disability and health care expense, resulting in more than 1 million office visits per year in the United States. In addition to health care expense, the societal cost of these injuries includes lost job wages and production. In competitive or professional athletes, this vocational loss may have extreme consequences. Soft tissue healing in vivo is often a...

Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?

N;

I-36: Preimplantation Genetic Diagnosis - Where Have We Been and Where Are We Going

Preimplantation genetic diagnosis (PGD) is now considered routine in IVF laboratories with micromanipulation capability and access to genetic diagnostic services. The past two decades have witnessed a dramatic increase in the use of PGD, the number of cycles performed, and the indications for which PGD has been used. This increase has been mirrored by a slow, but steady, increase in the range o...

Where are we now? Where are we going?